Achieve Life Sciences, Inc. financial data

Symbol
ACHV on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
22722 29 Th Dr. Se, Suite 100, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ONCOGENEX PHARMACEUTICALS, INC. (to 7/31/2017), SONUS PHARMACEUTICALS INC (to 8/7/2008)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 286 % +60.8%
Debt-to-equity 89.3 % -79.3%
Return On Equity -117 % +86.3%
Return On Assets -61.7 % +61.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.3M shares +62.7%
Common Stock, Shares, Outstanding 34.3M shares +62.7%
Entity Public Float 90.8M USD +92.5%
Common Stock, Value, Issued 103K USD +14.4%
Weighted Average Number of Shares Outstanding, Basic 34.3M shares +80.2%
Weighted Average Number of Shares Outstanding, Diluted 34.3M shares +80.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.6M USD -52.4%
General and Administrative Expense 11.8M USD +5.12%
Costs and Expenses 25.4M USD -36.2%
Nonoperating Income (Expense) -2.17M USD -24.1%
Net Income (Loss) Attributable to Parent -27.5M USD +33.7%
Earnings Per Share, Basic -1.08 USD/shares +64.6%
Earnings Per Share, Diluted -1.08 USD/shares +64.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.8M USD -41.1%
Cash, Cash Equivalents, and Short-term Investments 61.3M USD
Assets, Current 62.5M USD +137%
Property, Plant and Equipment, Net 13K USD +225%
Operating Lease, Right-of-Use Asset 35K USD -63.2%
Goodwill 1.03M USD 0%
Assets 64.8M USD +124%
Accounts Payable, Current 550K USD +52.4%
Employee-related Liabilities, Current 1.35M USD +9.32%
Liabilities, Current 13.7M USD +298%
Operating Lease, Liability, Noncurrent 6K USD -91.3%
Liabilities 22.5M USD +17.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -7K USD -275%
Retained Earnings (Accumulated Deficit) -181M USD -18%
Stockholders' Equity Attributable to Parent 42.3M USD +336%
Liabilities and Equity 64.8M USD +124%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.29M USD +36.3%
Net Cash Provided by (Used in) Financing Activities 56.1M USD +119283%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 34.3M shares +62.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.8M USD
Deferred Tax Assets, Valuation Allowance 73.2M USD +11.7%
Deferred Tax Assets, Gross 73.6M USD +11.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.47M USD -2.83%
Property, Plant and Equipment, Gross 256K USD -15.5%
Operating Lease, Liability, Current 37K USD -38.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 48.9M USD +12.6%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 761K USD 0%
Operating Lease, Payments 60K USD +3.45%
Amortization of Intangible Assets 200K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 346K USD -12%
Interest Expense 3.19M USD +37.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%